Navigation Links
Vion Pharmaceuticals Announces Initiation of Clinical Trial of Cloretazine(R) (VNP40101M) in Combination with Stem Cell Transplantation
Date:12/4/2007

NEW HAVEN, Conn., Dec. 4 /PRNewswire-FirstCall/ -- VION PHARMACEUTICALS, INC. (Nasdaq Capital Market: VION) today announced the start of an investigator-sponsored Phase I clinical trial of its lead anticancer agent Cloretazine(R) (VNP40101M) in combination with hematopoietic cell transplant (HCT) in patients with various advanced hematologic malignancies. The trial is being conducted under the direction of Roy Jones, M.D., Ph.D., a professor in the Department of Stem Cell Transplantation at The University of Texas M.D. Anderson Cancer Center.

The objective of the trial is to define the maximum tolerated dose (MTD) of Cloretazine(R) (VNP40101M) when given to patients of 18 to 65 years of age with poor-prognosis leukemia, lymphoma, and Hodgkin's disease who are undergoing either an allogeneic or autologous HCT.

Ann Cahill, Vice President of Clinical Development, commented, "Both patients and physicians are searching for ways to improve outcomes after stem cell transplantation. Patients with advanced disease are particularly in need of new therapies." Ms. Cahill concluded, "We are hopeful that Cloretazine(R) (VNP40101M) can make a contribution in the stem cell transplant setting."

Vion Pharmaceuticals, Inc. is committed to extending the lives and improving the quality of life of cancer patients worldwide by developing and commercializing innovative cancer therapeutics. Vion has two agents in clinical trials. Cloretazine(R) (VNP40101M), a unique alkylating agent, is being evaluated in a Phase II pivotal trial as a single agent in elderly patients with previously untreated de novo poor-risk acute myelogenous leukemia. Clinical trials of Cloretazine(R) (VNP40101M) as a single agent in small cell lung cancer, with temozolomide in brain tumors, and with stem cell transplantation in advanced hematologic malignancies, are also being conducted. Triapine(R), a potent inhibitor of a key step in DNA synthesis, is being evaluated in clinical trials spon
'/>"/>

SOURCE Vion Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2 3

Related medicine technology :

1. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
2. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
3. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
4. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
5. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
6. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
7. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
8. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
9. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
10. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
11. Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/25/2009)... , PHILADELPHIA, Nov. 25 /PRNewswire-FirstCall/... Michael J. McKelvey, the Company,s President and ...ce President and CFO, are scheduled to present at ...ce at 1:30 PM EST on December 1, 2009 in New York ...s the presentation by visiting the Company,s corpo...
(Date:11/25/2009)..., COLLEGE PARK, Md., Nov. 25 /PRNewswire-USNewswi...oping a shaving cream-like foam that stops severe ...Promising Security Idea category of the Global Sec...oday. ,, Selected from more than 100 entries fr... invention at the GSC Security Summit conference h...
(Date:11/25/2009)... , NEW YORK, Nov. 25 Reportlin...t is available in its catalogue: ,, Mammograp... http://www.reportlinker.com/p0164330/Mammography..., Rising incidence of breast cancer in industrial...factor influencing growth in the mammography marke...
Breaking Medicine Technology:ERT to Present at the 21st Annual Piper Jaffray Health Care Conference on December 1, 2009 2Remedium Technologies Wins Most Promising Security Idea at Global Security Challenge 2009 with Blood-Clotting Foam 2Remedium Technologies Wins Most Promising Security Idea at Global Security Challenge 2009 with Blood-Clotting Foam 3Reportlinker Adds Mammography Equipment - A Global Market Perspective 2Reportlinker Adds Mammography Equipment - A Global Market Perspective 3Reportlinker Adds Mammography Equipment - A Global Market Perspective 4Reportlinker Adds Mammography Equipment - A Global Market Perspective 5Reportlinker Adds Mammography Equipment - A Global Market Perspective 6Reportlinker Adds Mammography Equipment - A Global Market Perspective 7Reportlinker Adds Mammography Equipment - A Global Market Perspective 8AIDS like Illness Found in African Chimps 52444 1AIDS like Illness Found in African Chimps 52444 2IHPA Launches Consumer Awareness Campaign for Hurricane Protection 52442 1IHPA Launches Consumer Awareness Campaign for Hurricane Protection 52442 2IHPA Launches Consumer Awareness Campaign for Hurricane Protection 52442 3Major Study of Malpractice Insurance Finds No Basis to Limit Liability of Unsafe Health Care Providers 52440 1Major Study of Malpractice Insurance Finds No Basis to Limit Liability of Unsafe Health Care Providers 52440 2
..., Inc.,(Nasdaq: PCYC ) today announced that it h...ation study to evaluate the safety and tolerabilit...bitor of Bruton,s tyrosine kinase, or Btk,as a pot...ractory B-cell,non-Hodgkin,s lymphoma (NHL). Thi...d in humans, and is Pharmacyclics, fourth product ...
..., Binding Capabilities for Antibody Pipeline And N...9 InNexus Biotechnology Inc. (Toronto Stock Excha...opment company commercializing the next generation... Dynamic Cross Linking (DXL(TM)), announced today ...s lead preclinical candidate DXL625 (CD20) for the...
Other Medicine Technology:Pharmacyclics Initiates Phase 1 Clinical Trial of Novel Oral Btk Inhibitor for Refractory B-cell Non-Hodgkin's Lymphoma 2Pharmacyclics Initiates Phase 1 Clinical Trial of Novel Oral Btk Inhibitor for Refractory B-cell Non-Hodgkin's Lymphoma 3Pharmacyclics Initiates Phase 1 Clinical Trial of Novel Oral Btk Inhibitor for Refractory B-cell Non-Hodgkin's Lymphoma 4Pharmacyclics Initiates Phase 1 Clinical Trial of Novel Oral Btk Inhibitor for Refractory B-cell Non-Hodgkin's Lymphoma 5AACR Data Highlights InNexus Preclinical Antibody Candidate 2
(Date:11/27/2009)...-SEINE, France, Nov. 27 Team Garmi...ing team dedicated to ethical sporting and develop...unced today that it will become Team Garmin-Transi...a new sponsor of the team. Transitions Optical is ...ar, offering the most advanced photochromic techno...
(Date:11/27/2009)..., SEATTLE, Nov. 27 Allrecipes.co...gh Thanksgiving traffic numbers, with more than 2....oviding a clear picture of what was served on the ...ksgiving meal in 2009 weighed in at 2,225 calories...s feast. According to the Allrecipes site, Sweet ...
(Date:11/26/2009).... 27 With cold and flu season upon...practices to control the spread of infections and ...only to keep ourselves healthy, but to avoid trans...y, RN, MS, CIC (certified in infection-control), n...onal health at Hospital for Special Surgery (HSS) ...
(Date:11/26/2009)...when on an emotional rollercoaster, study finds ,...Call it the fear factor meets the jubilant sports ...especially those who root for the winning team -- ...contested match and victory was in doubt, producin... that this Thanksgiving weekend as you,re glued to...
(Date:11/26/2009)... Ennis & Ennis, P.A. is offering free nationwi... Yasmin birth control pills who have suffered a De...ke, Heart Attack or other related cardiac issues o...ll free at 1-800-856-6405 or go to the firm’...t an online case evaluation form. , ...
Breaking Medicine News(10 mins):Health News:Team Garmin-Slipstream Officially Re-named Team Garmin-Transitions With Addition of Transitions Optical as New Sponsor 2Health News:Team Garmin-Slipstream Officially Re-named Team Garmin-Transitions With Addition of Transitions Optical as New Sponsor 3Health News:It's Black Friday - Time to Shop Off the Calories! Allrecipes Finds Average Thanksgiving Meal Weighed in at 2,225 Calories 2Health News:It's Black Friday - Time to Shop Off the Calories! Allrecipes Finds Average Thanksgiving Meal Weighed in at 2,225 Calories 3Health News:It's Black Friday - Time to Shop Off the Calories! Allrecipes Finds Average Thanksgiving Meal Weighed in at 2,225 Calories 4Health News:Infection-Control Strategies at Leading Hospital Can be Adapted for Everyday Use 2Health News:Infection-Control Strategies at Leading Hospital Can be Adapted for Everyday Use 3Health News:Infection-Control Strategies at Leading Hospital Can be Adapted for Everyday Use 4Health News:Watching the Nail-Biting Big Game Hurts So Good 2Health News:Watching the Nail-Biting Big Game Hurts So Good 3Health News:Ennis & Ennis, P.A. Announces Nationwide Free, Confidential, Consultations For Users Of Yaz And Yasmin Birth Control Pills 2Health News:Ennis & Ennis, P.A. Announces Nationwide Free, Confidential, Consultations For Users Of Yaz And Yasmin Birth Control Pills 3
... Sweden, May 15 The Karolinska Institutet in St...gree to Kevin J. Tracey, MD, director and chief ex...ical Research in Manhasset, NY. , , (Photo: ht...the immune system, joins a long and distinguished ...
...ombination should enable HealthWarehouse.com to ac...ription drug program , , CINCINNATI, May 15 Heal...orporation, and Clacendix, Inc. (OTC Bulletin Boar... and execute the HealthWarehouse.com business plan...
...Hungary, May 15 Bertalan Mesko, medical blogger a...urce, Diabetes 2.0 , that aims to provide diabe...ended and comprehensive package containing quality.... All the web 2.0 tools patients and their healthc...
....C. Pathfinders, a program designed to care for t...en found to help women with terminal cancer cope a...study led by researchers in the Duke Comprehensive...ith metastatic breast cancer and a six month life ...
...e Lawmakers to ,Help Us Choose Home, as Home Care ...re is Cost-Effective , , WASHINGTON, May 15 ...ates traveled to Capitol Hill, fighting to preserv...enefit in the Obama Administration,s proposed 2010...
..., May 15 The following is a statement by Jeff Lev...s Health (TFAH) on the appointment of Thomas R. Fr... Disease Control and Prevention (CDC): , , "Dr. F...rom the tough problems. His innovative strategies ...
Other Medicine News:Health News:Karolinska Institutet Awards Honorary Degree to Feinstein Institute CEO Kevin J. Tracey, MD 2Health News:HealthWarehouse.com, Inc. Announces Completion of Business Combination With Clacendix, Inc. 2Health News:HealthWarehouse.com, Inc. Announces Completion of Business Combination With Clacendix, Inc. 3Health News:Program focused on body, mind and spirit helps women with breast cancer cope 2Health News:'50 Nurses from 50 States' Visit Capitol Hill to Preserve Home Health Medicare Benefit for their Patients and All Americans 2Health News:'50 Nurses from 50 States' Visit Capitol Hill to Preserve Home Health Medicare Benefit for their Patients and All Americans 3Health News:Trust for America's Health Supports Appointment of Thomas Frieden to Lead CDC 2
Williams Micro Discectomy Instruments
Seletz-Gelpi Laminectomy Retractor
Valin Hemilaminectomy Retractor
Scoville Hemilaminectomy Retractor
Medicine Products: